中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人民币9581.5万元， 同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

智通财经APP讯，中生北控生物科技(08247)发布截至2025年6月30日止6个月中期业绩，集团营业收入人 民币9581.5万元，同比减少28.4%;股东应占亏损1797.6万元，同比扩大36.37%;每股亏损0.124元。 ...

提名委員會職權範圍及程序 定義 | 董事會 | 指本公司的董事會 | | --- | --- | | 本公司 | 指中生北控生物科技股份有限公司 | | 董事 | 指本公司的董事 | | 《上市規則》 | 指聯交所GEM《證券上市規則》 | | 本集團 | 指本公司及其附屬公司 | | 獨立非執行董事 | 指本公司的獨立非執行董事 | | 提名委員會 | 指董事會根據本職權範圍及程序通過之決議而成立 | | | 的提名委員會 | | 高級管理人員 | 指本公司的高級管理人員 | | 聯交所 | 指香港聯合交易所有限公司 | 成立提名委員會的目的 董事會成立提名委員會的目的是為了更好地處理有關董事會成員的提名及組成之 事宜，並提高董事會的工作效率。 * 僅供識別 1 利益披露 組成 5. 提名委員會的每一位成員應向提名委員會披露其在由提名委員會決定的任何 事項中享有的任何個人財務利益，及涉及其的因該等事項引發的任何潛在利 益衝突。任何享有該等利益或涉及該等潛在利益衝突的成員應回避與該等利 益或潛在利益衝突有關的提名委員會決議的表決、回避參與涉及該等決議的 任何討論，若董事會要求，有關成員應向提名委員會請辭。 會 ...

NOTIFICATION LETTER 通知信函 29 August 2025 Dear Non-registered Shareholder(s) (Note 1) , Biosino Bio-Technology and Science Incorporation (the "Company") – Notification of publication of Interim Report 2025 (the "Current Corporate Communication") Yours faithfully, For and on behalf of the Board Biosino Bio-Technology and Science Incorporation Tung Woon Cheung, Eric Company Secretary Notes: 各位非登記股東 （附註1） ： 中生北控生物科技股份有限公司（「本公司」） －2025年中期報告（「本次公司通訊」）之發佈通知 本 公 司 的 本 次 公 司 通 訊 之 中、英 文 版 本 已 分 別 上 載 於 本 公 司 網 站 (www ...

NOTIFICATION LETTER 通知信函 29 August 2025 Dear Registered Shareholders, Biosino Bio-Technology and Science Incorporation (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.zhongsheng.com.cn and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). ...

中 生 北 控 生 物 科 技 股 份 有 限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION 中期報告 2025 Interim Report 2025 中 生 北 控 生 物 科 技 股 份 有 限 公 司 BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION (Incorporated in the People's Republic of China with limited liability) (Stock Code : 8247) 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供一個上市 的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後 方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他老練投資者。 由於GEM 上市公司新興的性質所然，在GEM 買賣的證券可能會較於聯交所主板買賣之證 券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及 ...

中期業績公佈 截至二零二五年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審 慎周詳的考慮後方作出投資決定。GEM 的較高風險及其他特色表示GEM 較適合 專業及其他老練投資者。 由於GEM上市公司新興的性質所然，在GEM買賣的證券可能會較於聯交所主板買 賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通 量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 本公佈乃遵照GEM證券上市規則（「《GEM上市規則》」）的規定提供有關中生北 控生物科技股份有限公司（「本公司」，與其附屬公司統稱為「本集團」）的資料，本 公司各董事（「董事」）願就本公佈共同及個別承擔全部責任。各董事經作出一切合 理查詢後確認，就彼等所深知及確信：(1)本公佈所載資料在各重大方面均屬準確 完整，且無誤導 ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公佈之 內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不會就本 公佈全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 董事會會議通告 中生北控生物科技股份有限公司（「本公司」）的董事（「董事」）會（「董事會」）謹此 宣佈，董事會會議將於二零二五年八月二十九日（星期五）上午九時正以通訊方式 召開，以處理下列事項： 承董事會命 中生北控生物科技股份有限公司 公司秘書 董渙樟 中國，北京，二零二五年八月十八日 1 1. 省覽及批准本公司及其附屬公司（「本集團」）截至二零二五年六月三十日止 六個月的未經審計綜合中期業績； 2. 批准於聯交所GEM 網站刊登本集團截至二零二五年六月三十日止六個月的 中期業績公告； 3. 考慮派付中期股息（如有）； 4. 考慮暫停辦理本公司過戶登記手續（如需要）；及 5. 處理任何其它事項。 於本公佈日期，董事會成員包括： 主席兼執行董事 陳正永先生 副主席兼執行董事 李忠華先生 總裁兼執行董事 陳鵬先生 副主席兼非執行董事 楊鵬先生 非執行董事 高光俠博士及沈勝博士 獨立非執行董事 ...

FF301 | 144,707,176 | | --- | | RMB | | 本月底法定/註冊股本總額： | | 2. 股份分類 | 普通股 | 股份類別 | | 其他類別 (請註明) | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 80,421,033 | RMB | | 1 RMB | | 80,421,033 | 公司名稱: 中生北控生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H ...

Financial Performance - The annual operating revenue reached approximately RMB 263.1 million, a decrease of about 9.0% compared to the previous year[16] - The annual loss amounted to approximately RMB 56.9 million, compared to a loss of RMB 19.2 million in the previous year[16] - The company's operating revenue for the year was approximately RMB 263.1 million, a decrease of about 9.0% compared to RMB 289.1 million in the previous year[34] - Gross profit for the year was approximately RMB 108.4 million, down about 14.9% from RMB 127.4 million last year, resulting in a gross margin of approximately 41.2% compared to 44.1% in the previous year[35] - The company reported a net loss of approximately RMB 56.9 million for the year, compared to a loss of approximately RMB 19.2 million in the previous year, primarily due to declines in operating revenue and gross profit[41] - Basic and diluted loss per share for the year was RMB (0.294), compared to RMB (0.080) in the previous year, reflecting a worsening financial position[198] - Financial asset impairment losses increased to RMB 6,528,000 from RMB 712,000 in 2023, highlighting growing concerns over asset quality[198] Dividend Policy - The company did not recommend the distribution of any dividends for the fiscal year ending December 31, 2024, consistent with the previous year[19] - The group reported no dividends for the fiscal year ending December 31, 2024, consistent with the previous year[121] - As of December 31, 2024, the company recorded a cumulative loss of approximately RMB 53,196,000, with no distributable reserves available for shareholders, compared to approximately RMB 14,433,000 as of December 31, 2023[129] Market Environment - The IVD industry experienced significant changes, with the end of COVID-19 testing and a shift in the market landscape, leading to a decline in product sales prices[20] - Despite challenges, the demand for disease testing is increasing due to an aging population and rising chronic disease rates, supported by increased government investment in health[20] - The ongoing tightening of cost control policies under the national medical insurance system has further compressed the company's profit margins[20] - The company faced a 30%-40% average price drop in key biochemical diagnostic reagent products due to centralized procurement, impacting overall revenue[28] - The demand for chronic disease diagnostic IVD products is increasing due to an aging population, although the company needs to enhance market promotion and product innovation to keep pace[29] Research and Development - R&D investment for the year was approximately RMB 33.4 million, with several new diagnostic systems and products approved for market, including nine newly registered products[26] - Research and development expenses totaled approximately RMB 33.4 million, a decrease of about 6.7% from RMB 35.8 million in the previous year[38] - The company is committed to increasing R&D investment and accelerating the development of new products, particularly in chemiluminescence reagents and molecular diagnostics[45] - The company is focused on enhancing its research and development capabilities to mitigate risks associated with technological obsolescence in the IVD industry[100] Strategic Initiatives - The company is exploring new opportunities for growth amid the crisis, driven by technological innovation in the IVD sector[20] - The company plans to strengthen collaborations with research institutions and universities to boost innovation capabilities and attract talent[22] - The company is actively expanding its market channels both domestically and internationally, with a focus on Southeast Asia, where it has successfully entered the market with biochemical diagnostic reagent products[33] - The company aims to strengthen customer relationships by providing personalized solutions and one-stop services, enhancing customer satisfaction and product stickiness[33] - The company has a strategic plan to explore potential mergers and acquisitions to strengthen its market position and product offerings[167] Corporate Governance - The board of directors is responsible for overseeing the company's management, business strategy, and financial performance[60] - The board held five meetings in 2024 with an average attendance rate of 96%[66] - The company has established mechanisms to ensure independent opinions from non-executive directors, including annual reviews of their contributions[62] - The company has adopted a standard code for securities trading by directors, ensuring compliance with GEM Listing Rules[69] - The company has maintained a robust corporate governance system, adhering to all code provisions except for the internal audit function, which is currently not established due to the group's scale and operational structure[148] Risk Management - The company has established a comprehensive risk management system to identify and manage key operational risks[99] - The board regularly reviews the effectiveness of internal controls and risk management systems to protect the interests of the company and its shareholders[97] - The company has implemented measures to manage accounts receivable effectively, reducing the risk of bad debts as sales scale increases[102] - The company has established an emergency mechanism to respond to natural disasters and public health events, ensuring rapid response capabilities[102] Employee and Talent Management - The total employee cost for the year was approximately RMB 103 million, up from RMB 99 million in 2023[53] - The company employed a total of 499 full-time employees as of December 31, 2024, down from 537 in 2023[53] - The company is committed to attracting and retaining high-quality talent to maintain its competitive advantage in the IVD industry[101] - The company will continue to focus on training and long-term development opportunities for female employees[81] Financial Compliance - The board confirmed compliance with all relevant laws and regulations that significantly impact the group's business and operations during the year[130] - The company has implemented measures to ensure compliance with the GEM Listing Rules and relevant laws and regulations[57] - The independent non-executive directors confirmed their independence as per the GEM Listing Rules[134]